Malignant melanotic nerve sheath tumor
Citation, DOI & article data
Malignant melanotic nerve sheath tumors (previously known as melanotic schwannomas) are uncommon aggressive tumors commonly associated with PRKAR1A mutations and Carney complex.
Initially, these tumors were believed to be variants of schwannomas and were thus named melanotic schwannomas, not to be confused with conventional schwannomas that can sometimes accumulate neuromelanin 7,8.
These tumors occur most often in the third through fifth decades, younger in patients with Carney complex 1,5,7,10.
Clinical presentation will depend on the location of the tumor and whether or not it has undergone malignant degeneration with metastases. As there is a predilection for spinal nerves, cord compression or focal neurology, both sensory and motor, is encountered 6. Larger peripheral lesions may merely present as palpable lumps.
Melanotic nerve sheath tumors arise from a common precursor to both Schwann cells and melanocytes 7-9.
Over half of individuals diagnosed with these tumors have underlying Carney complex 1-3,9.
Malignant melanotic nerve sheath tumors appear as well-circumscribed masses of variable pigmentation ranging from grey to black, depending on the amount of melanin 3,9.
Histologic assessment can be challenging due to heavy melanin pigmentation. The cells are variable in shape, from spindle-shaped to polygonal. They occur in two forms depending on the presence or absence of psammoma bodies, found in approximately half of cases 1-6,9:
The appearances of malignant melanotic nerve sheath tumors are similar to schwannomas except that they usually have intrinsic high T1 signal and T2 signal loss due to the presence of melanin 4.
Treatment and prognosis
Although complete resection is usually curative, malignant melanotic nerve sheath tumors have a higher local recurrence rate than other schwannomas (15-35%) 3. Approximately 10% of these tumors are malignant 1,3.
Metastatic disease occurs in a significant minority and is most commonly reported in the lungs and pleura 6. Importantly, metastatic disease can be encountered even when no malignant features are identified in the primary tumor 9.
The differential is primarily that of other neurogenic tumors and melanotic lesions including 6:
- 1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK "WHO Classification of Tumours of the Central Nervous System. 4th Edition Revised" ISBN: 9789283244929
- 2. Merat R, Szalay-Quinodoz I, Laffitte E, Kaya G. Psammomatous Melanotic Schwannoma: A Challenging Histological Diagnosis. Dermatopathology (Basel, Switzerland). 2 (3): 67-70. doi:10.1159/000442708 - Pubmed
- 3. Shields LB, Glassman SD, Raque GH, Shields CB. Malignant psammomatous melanotic schwannoma of the spine: A component of Carney complex. Surgical neurology international. 2: 136. doi:10.4103/2152-7806.85609 - Pubmed
- 4. Hoover JM, Bledsoe JM, Giannini C, Krauss WE. Intramedullary melanotic schwannoma. Rare tumors. 4 (1): e3. doi:10.4081/rt.2012.e3 - Pubmed
- 5. Koeller KK, Shih RY. Intradural Extramedullary Spinal Neoplasms: Radiologic-Pathologic Correlation. (2019) Radiographics : a review publication of the Radiological Society of North America, Inc. 39 (2): 468-490. doi:10.1148/rg.2019180200 - Pubmed
- 6. Alexiev B, Chou P, Jennings L. Pathology of Melanotic Schwannoma. (2018) Archives of pathology & laboratory medicine. 142 (12): 1517-1523. doi: 10.5858/arpa.2017-0162-RA
- 7. Stemmer-Rachamimov AO, Jo VY, Rodriguez FJ, Reuss DE, Schwannoma. In: WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 6). https://publications.iarc.fr/601
- 8. Roman Hernandez E, Valasareddi S, Adkison J, Awan H, Basarakodu K, Velayati A. Can Discord Domain-Containing Receptor 2 Mutation Act as a Disease Modifier for PRKAR1A Associated Melanotic Schwannoma? Case Rep Oncol. 2021;14(2):826-31. doi:10.1159/000515331 - Pubmed
- 9. Reuss DE, Jo VY, Folpe AL, Stemmer-Rachamimov AO, Melanotic nerve sheath tumour. In: WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 6). https://publications.iarc.fr/601